New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
06:21 EDTVRX, GS, AGN, SHPG, ABBVShire hires Goldman as it confronts takeover offer, NY Times reports
Shire (SHPG) has hired Goldman Sachs (GS) as an adviser as it looks to fend off a takeover offer, the New York Times reports, citing sources. Shire recently rejected a $46B bid from AbbVie (ABBV), and Allergan (AGN), which is fending off takeover offers from Valeant (VRX), has been rumored as a potential bidder for Shire. Reference Link
News For SHPG;GS;ABBV;AGN;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 27, 2015
06:25 EDTABBVAbbVie reinstated with an Overweight at JPMorgan
JPMorgan reinstated its Overweight rating on shares of AbbVie and raised its price target for shares to $75 from $73. The firm views the valuation as "inexpensive" and views the Pharmacyclics acquisition as adding a "solid" growth platform.
May 26, 2015
19:16 EDTABBVEnanta says may receive $30M milestone payment from AbbVie upon Japan approval
In reference to the release of GIFT-1 study data, Enanta (ENTA) stated that upon commercialization regulatory approval [sic] in Japan of AbbVie's (ABBV) treatment regimen related to GIFT-1, Enanta will be entitled to a $30M milestone payment from AbbVie. In addition, Enanta will be eligible to receive annually tiered royalties, ranging from the low double digits up to 20%, on AbbVies aggregate net sales of all paritaprevir-containing regimens, including 45% of AbbVies worldwide net sales of any two direct-acting antivirals regimen.
19:07 EDTABBVAbbVie presents phase 3 GIFT-I data, says achieved primary endpoint
Subscribe for More Information
10:46 EDTABBVAnthem sued for denying coverage for Gilead's Harvoni, WSJ says
Subscribe for More Information
08:32 EDTABBVAbbVie completes acquisition of Pharmacyclics
Subscribe for More Information
08:17 EDTGSGoldman hired by Carlyle for potential stake sale in Telecable, Reuters reports
Goldman Sachs (GS) has been hired by Carlyle (CG) to advise the company on a possible sale of its 85% stake in Telecable, a Spanish telecoms operator, Reuters reports, citing two sources. Reference Link
08:14 EDTSHPGBoston Biotech Conferences to hold a conference
Subscribe for More Information
08:03 EDTABBVInfinity Pharmaceuticals reports preclinical data for duvelisib
Subscribe for More Information
06:04 EDTGSGoldman seeks to target $1B in renewable energy bonds in Japan, Reuters says
Subscribe for More Information
May 22, 2015
08:00 EDTABBVAbbVie announces expiration of HSR waiting period for Pharmacyclics acquisition
AbbVie (ABBV) announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for AbbVie's purchase of Pharmacyclics (PCYC) has expired today. The expiration satisfies the exchange offer condition with respect to the approvals and clearances required under antitrust laws. Assuming that the other customary exchange offer conditions are satisfied, including a minimum tender of at least a majority of outstanding Pharmacyclics shares, it is expected that the exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics will expire today at 5:00 p.m., New York City time, without any further extension.
May 21, 2015
19:54 EDTVRXValeant to expand Canadian presence in coming years, Globe and Mail says
Subscribe for More Information
08:04 EDTABBVAbbVie announces offer consideration for acquisition of Pharmacyclics
AbbVie (ABBV) announced the per share offer consideration amounts pursuant to its previously announced offer to acquire each outstanding share of common stock of Pharmacyclics (PCYC) for a mix of cash and AbbVie common stock, as described in the Registration Statement on Form S-4 filed with the SEC by AbbVie on March 23, 2015, as amended. The mixed consideration will consist of $152.25 in cash and 1.6639 shares of AbbVie common stock and, subject to proration, the all-stock consideration will consist of 3.9879 shares of AbbVie common stock.
07:58 EDTABBVDeutsche sees AbbVie shares getting to $80 over summer
Deutsche Bank sees pipeline readouts over the summer pushing shares of AbbVie to $80. The firm keeps a Buy rating on the stock with an $80 price target after meting with management.
07:37 EDTSHPG, ABBVPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 20, 2015
09:07 EDTABBVJohnson & Johnson says exploring eight new indications for Imbruvica
Imbruvica is jointly developed and commercialized by Pharmacyclics (PCYC) and Johnson & Johnson (JNJ) subsidiary Janssen Biotech. AbbVie (ABBV) is in the process of acquiring Pharmacyclics.
08:21 EDTGSATM data theft soars to highest rate in two decades, WSJ says
Subscribe for More Information
07:21 EDTABBVUBS to hold a conference
Subscribe for More Information
06:37 EDTVRXSources: Valeant in talks to buy Amoun Pharmaceutical, Bloomberg reports
Subscribe for More Information
06:32 EDTVRXValeant CEO sees quintupling in Asia sales by 2020, Reuters reports
Subscribe for More Information
May 19, 2015
08:57 EDTABBVLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use